Nicotine Addiction in Schizophrenia, Availability of Better Treatment Options as are in General Population | OMICS International | Abstract
ISSN: 1522-4821

International Journal of Emergency Mental Health and Human Resilience
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Nicotine Addiction in Schizophrenia, Availability of Better Treatment Options as are in General Population

Saeed Ahmed MD1*, Reena MD2, Nuzhat Hussain MD3, Rizwan Ahmed4, Sharmeen Amin5, Samreen Ahmed6, Washdave7

1Department of Psychiatry, Thomas Jefferson University Hospital, Philadelphia

2People’s Medical College, Nawabshah

3Dow University of Health Sciences, Karachi

4Liaquat College of Medicine and Dentistry, Karachi

5Jinnah Sindh Medical University, Karachi

6NYU Langone Medical Center

7Psych Care Consultants Research, St Louis

*Corresponding Author:
Saeed Ahmed MD
Department of Psychiatry
Thomas Jefferson University Hospital, Philadelphia
E-mail: [email protected]


This article reviews literature regarding smoking cessation in Schizophrenia population, its harmful effects on health, finances, role of mental health care providers and better available options for treatment as are in general population. This population not only smokes at higher rates, but also has higher nicotine dependence with lower cessation rates than general population, people of schizophrenia have truncated life span due to smoking related diseases and premature mortality compared with the general population. Contrary to traditional reasoning that this population is not motivated or able to tolerate smoking cessation, but there is extensive literature that negates such rationale, even provides better treatment options to address this huge public health burden. Our review will mainly focusing treatment options particularly drug Varenicline, that shows most effective and promising results in patients of schizophrenia for smoking cessation as in general population, moreover different combination therapies, few new interventions, as well as some clinical areas will be discussed those need to be studied further in future.